<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39422246</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8336</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Expert review of anti-infective therapy</Title><ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14787210.2024.2419579</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate the effectiveness of oral antiviral agents - nirmatrelvir - ritonavir or molnupiravir in non-hospitalized COVID-19 patients aged &lt; 60 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective cohort study analyzed data of patients aged 18-60 years diagnosed with COVID-19 between 1 January 2022, and 30 June 2023. Propensity score matching was used to balance the demographic and clinical characteristics of patients receiving oral antivirals (nirmatrelvir - ritonavir or molnupiravir) and untreated controls. The primary outcome was a composite of all-cause emergency department visits, hospitalizations, or mortality within 30 days. The secondary outcomes included each individual component of the primary composite outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Two matched cohorts (antiviral group and control group) comprising 52,585 patients with balanced baseline characteristics were created using propensity score-matching. During follow-up period, the antiviral group demonstrated a lower risk of the primary outcome than the control group (hazard ratio [HR] 0.772, 95% confidence interval [CI] 0.736-0.808, <i>p</i> &lt; 0.001). The antiviral group also exhibited a reduced risk of individual secondary outcomes, including emergency department visits (HR 0.780, 95% CI, 0.738-0.825), hospitalization (HR 0.755, 95% CI, 0.715-0.840), and mortality (HR 0.297, 95% CI, 0.147-0.600).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Oral antiviral agents were associated with lower risks of all-cause emergency department visits, hospitalizations, and mortality in non-hospitalized COVID-19 patients aged &lt; 60 years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Wan-Hsuan</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0002-2517-1792</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiau</LastName><ForeName>Bo-Wen</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Ya-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Center of Integrative Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jheng-Yan</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-3290-1909</Identifier><AffiliationInfo><Affiliation>Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ting-Hui</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Po-Yu</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Min-Hsiang</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chih-Cheng</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-9416-4094</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anti Infect Ther</MedlineTA><NlmUniqueID>101181284</NlmUniqueID><ISSNLinking>1478-7210</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV2-2</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword><Keyword MajorTopicYN="N">nirmatrelvir–ritonavir</Keyword><Keyword MajorTopicYN="N">propensity score matching</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39422246</ArticleId><ArticleId IdType="doi">10.1080/14787210.2024.2419579</ArticleId></ArticleIdList></PubmedData></PubmedArticle>